Study of Sorafenib and Transarterial Chemoembolization (TACE) versus TACE to Treat Advanced Hepatocellular Carcinoma

Trial Profile

Study of Sorafenib and Transarterial Chemoembolization (TACE) versus TACE to Treat Advanced Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Sorafenib (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date (Mar 2018) added as reported by Chinese Clinical Trial Register record.
    • 09 Jan 2012 Planned number of patients changed to 360.
    • 09 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top